| __timestamp | Alnylam Pharmaceuticals, Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 1860000 |
| Thursday, January 1, 2015 | 60610000 | 2963000 |
| Friday, January 1, 2016 | 89354000 | 6961000 |
| Sunday, January 1, 2017 | 199365000 | 11779000 |
| Monday, January 1, 2018 | 382359000 | 13697000 |
| Tuesday, January 1, 2019 | 479005000 | 15749000 |
| Wednesday, January 1, 2020 | 588420000 | 18638000 |
| Friday, January 1, 2021 | 620639000 | 27196000 |
| Saturday, January 1, 2022 | 770658000 | 31739000 |
| Sunday, January 1, 2023 | 795646000 | 33491000 |
| Monday, January 1, 2024 | 975526000 |
In pursuit of knowledge
In the competitive world of biotechnology, managing operational costs is crucial for success. Alnylam Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc. offer a fascinating study in contrasts over the past decade. From 2014 to 2023, Alnylam's Selling, General, and Administrative (SG&A) expenses surged by over 1,600%, reflecting its aggressive expansion and market penetration strategies. In contrast, Protagonist Therapeutics maintained a more conservative growth, with SG&A expenses increasing by approximately 1,700% during the same period, albeit from a much smaller base.
Alnylam's SG&A expenses peaked in 2023, reaching nearly 800 million, a testament to its robust operational scale. Meanwhile, Protagonist's expenses, though significantly lower, showed a steady upward trend, indicating a strategic focus on sustainable growth. This analysis underscores the diverse approaches biotech companies take in balancing growth and efficiency, offering valuable insights for investors and industry stakeholders alike.
Vertex Pharmaceuticals Incorporated or Protagonist Therapeutics, Inc.: Who Manages SG&A Costs Better?
Regeneron Pharmaceuticals, Inc. or Alnylam Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Alnylam Pharmaceuticals, Inc. or Viking Therapeutics, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. or Protagonist Therapeutics, Inc.: Who Invests More in Innovation?
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Merus N.V.
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and MannKind Corporation
Who Optimizes SG&A Costs Better? Corcept Therapeutics Incorporated or Protagonist Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Protagonist Therapeutics, Inc. and Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Protagonist Therapeutics, Inc. or Galapagos NV